T4032 (unpreserved bimatoprost 0.01%)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for T4032 (unpreserved bimatoprost 0.01%), covering 2024-07-18 to 2024-07-18. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients [Phase 3]